Monday September 17, 8:00 am Eastern Time
Press Release
SOURCE: Adenosine Therapeutics
Adenosine Therapeutics' Collaborator To Present
New Sepsis Study At ICAAC
CHARLOTTESVILLE, VA--(INTERNET WIRE)--Sep 17, 2001-- The results of a study
investigating the use of the anti-inflammatory compound ATL 146e to combat sepsis will be
presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy
(ICAAC) in Chicago, Illinois. ATL 146e is an agonist of A2A adenosine receptors that has
been licensed to Adenosine Therapeutics, LLC.
Michael Scheld, M.D., a co-founder of Adenosine Therapeutics, LLC, and the
Wyeth-Ayerst Professor of Infectious Diseases at the University of Virginia, was the
Principal Investigator for the project. Guodong Fang, M.D., a research scientist from Dr.
Scheld's lab, will present the results from a mouse model of E. coli O26:B6 sepsis,
documenting that ATL 146e, when combined with the antibiotic, ceftriaxone, markedly
improved survival, while the antibiotic alone produced only partial protection. The session
will be held on Sunday, September 23rd, and Dr. Fang will present from 3:30-3:45 p.m. in
room S504 of the McCormick Place Lakeside Center, 2301 S. Lake Shore Drive. new
therapies are needed to improve the outcome of sepsis syndrome and septic shock. The
incidence of sepsis has been rising in the United States for the past 20 years, resulting in
estimated health care expenditures of $5-10 billion annually. There are 900,000 new cases
of sepsis treated each year. Despite the best care, the mortality rate for severe sepsis ranges
between 30 and 50 percent, resulting in a least 150,000 deaths a year and making sepsis the
11th leading cause of death in the United States.
Sepsis refers to the presence of systemic inflammatory response syndrome (SIRS), a clinical
response arising from an unspecified insult, brought on by an infectious process. In its more
severe forms, including septic shock, sepsis is coupled with hypotension, manifestations of
tissue hypoperfusion, and other perfusion abnormalities. ATL 146e, the compound cited as a
potential treatment of sepsis, belongs to a class of potent and selective adenosine A2A
agonists (alkynyladenosine compounds) which have been developed to treat a variety of
inflammatory disorders.
"This new research from our portfolio of adenosine A2A agonists is encouraging as a
potential treatment for the largely unmet need of sepsis patients, as well as an indicator of the
powerful anti-inflammatory effects of ATL 146e," said Robert S. Capon, CEO and
co-founder of Adenosine Therapeutics, LLC.
Adenosine Therapeutics focuses on the discovery and development of novel pharmaceutical products that target adenosine
receptor subtypes. Candidates for drug development are identified and screened using the Company's state of the art platform
technology. The Company was founded with the goal of bringing new adenosine-receptor selective drugs into clinical trials for a
broad range of potential indications. These drug indications include sepsis, heart attack, ischemia-reperfusion injury, vascular
injury, stroke, spinal cord injury, organ transplantation, COPD, asthma, diabetes, inflammatory bowel disease, retinopathy, and
to evoke new blood vessel formation in circulatory insufficiency.
Contact:
Robert Capon
804-971-6800 |
